Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma

REFERENCES

• Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, Bonomini S, Lunghi P, Hojden M, Genestreti G, Svaldi M, Coser P, Fattori P.P, Sammarelli G, Gazzola GC, Bataille R, Almici C, Caramatti C, Mangoni L, Rizzoli V. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 2003;102:638–645.
   PubMed Web of Science ®Google Scholar
• Hideshima T. Chauhan D. Podar, K. Schlossman RL. Richardson P. Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001;28:607–612.
   PubMed Web of Science ®Google Scholar
• Alexandrakis MG. Passam FJ. Ganotakis E. Dafnis E. Dambaki C. Konsolas J. Kyriakou DS. Stathopoulos E. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma. Clin Chem Lab Med 2004;42:1122–1126.
   PubMed Web of Science ®Google Scholar
• Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK. Greipp PR. Rajkumar SV. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004;104:1159–1165.
   PubMed Web of Science ®Google Scholar
• Alexandrakis M.G. Passam F.H. Sfiridaki A. Kandidaki E. Roussou P. Kyriakou D.S. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol 2003;72: 229–233.
   PubMed Web of Science ®Google Scholar
• Sezer O. Jakob C, Eucker J. Niemöller K. Gatz F. Wernecke K. Possinger K. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001;66:83–88.
   Google Scholar
• Pappa C.A, Tsirakis G, Kanellou P, Kaparou M, Stratinaki M, Xekalou A, Alegakis A, Boula A, Stathopoulos EN, Alexandrakis MG. Monitoring serum levels ELR + CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma. Cytokine 2011;56:616–620.
   PubMed Web of Science ®Google Scholar
• Sezer O, Niemöller K, Jakob C, Zavrski I, Heider U, Eucker J, Kaufmann O, Possinger K. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma. Ann Hematol 2001;80:598–601.
   PubMed Web of Science ®Google Scholar
• Uneda S, Matsuno F. Sonoki T. Tniguchi I. Kawano F. Hata H. Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells. Haematologica 2003;88:113–115.
   PubMed Web of Science ®Google Scholar
• Joshi S, Khan R, Sharma M, Kumar L, Sharma A. Angiopoietin-2: a potential novel diagnostic marker in multiple myeloma. Clin Biochem 2011;44:590–595.
   Google Scholar
• Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005;118:771–780.
   Google Scholar
• Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460–463.
   PubMed Web of Science ®Google Scholar
• Sillaber C, Mayerhofer M. Aichberger KJ. Krauth MT. Valent P. Expression of angiogenic factors in chronic myeloid leukaemia: role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications. Eur J Clin Invest 2004;34(Suppl 2):2–11.
   PubMedGoogle Scholar
• Koh GY. Kim I. Kwak HJ. Yun MJ. Leem JC. Biomedical significance of endothelial cell specific growth factor, angiopoietin. Exp Mol Med 2002;34:1–11.
   PubMed Web of Science ®Google Scholar
• Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG. Tie-2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 1997;81:567–574.
   PubMed Web of Science ®Google Scholar
• Choi K. Kennedy M. Kazarov A. Papadimitriou JC. Keller G. A common precursor for hematopoietic and endothelial cells. Development 1998;125:725–732.
   Google Scholar
• Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S, Trogan E. Expression of Tie2/TEK in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer 1998;77:51–56.
   PubMed Web of Science ®Google Scholar
• Yabkowitz R. Meyer S. Black T. Elliott G. Merewether LA. Yamane HK. Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation. Blood 1999;93:1969–1979.
   PubMed Web of Science ®Google Scholar
• Findley CM. Cudmore MJ. Ahmed A. Kontos CD. VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol 2007;27:2619–2626.
   PubMed Web of Science ®Google Scholar
• Quartarone E. Alonci A. Allegra A. Bellomo G. Calabrò L. D'Angelo A. Del Fabro V. Grasso A. Cincotta M. Musolino C. Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies. Eur J Haematol 2006;77:480–485.
   PubMed Web of Science ®Google Scholar
• Arai F. Hirao A. Ohmura M. Sato H. Matsuoka S. Takubo K, Ito K. Koh GY. Suda T. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004;118:149–161.
   PubMed Web of Science ®Google Scholar
• Anargyrou K, Terpos E, Vassilakopoulos TP, Pouli A, Sachanas S, Tzenou T, Masouridis S, Christoulas D, Angelopoulou MK, Dimitriadou EM, Kalpadakis C, Tsionos K, Panayiotidis P, Dimopoulos MA, Pangalis GA, Kyrtsonis MC. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica 2008;93:451–454.
   PubMed Web of Science ®Google Scholar
• Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002;99:11205–11210.
   PubMed Web of Science ®Google Scholar
• Kline M. Donovan K. Wellik L. Lust C. Jin W. Moon-Tasson L. Xiong Y. Witzig TE. Kumar S. Rajkumar SV. Lust JA. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leuk Res 2007;31:591–598.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607–618.
   PubMed Web of Science ®Google Scholar
• Terpos E, Anargyrou K, Katodritou E, Kastritis E, Papatheodorou A, Christoulas D, Pouli A, Michalis E, Delimpasi S, Gkotzamanidou M, Nikitas N, Koumoustiotis V, Margaritis D, Tsionos K, Stefanoudaki E, Meletis J, Zervas K, Dimopoulos MA. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. Int J Cancer 2012;130:735–742.
   PubMed Web of Science ®Google Scholar
• Schliemann C, Bieker R, Padro T, Kessler T, Hintelmann H, Buchner T, Berdel WE, Mesters RM. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 2006;91:1203–1211.
   PubMed Web of Science ®Google Scholar
• Martinelli S, Maffei R, Castelli I, Santachiara R, Zucchini P, Fontana M, Bonacorsi G, Leonardi G, Marasca R, Torelli G. Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis. Leuk Res 2008;32:593–597.
   PubMed Web of Science ®Google Scholar
• Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008;22:2247–2256.
   PubMed Web of Science ®Google Scholar
• Bhaskar A. Gupta R. Vishnubhatla S. Kumar L. Sharma A. Sharma MC. Das P. Thakur SC. Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma. Leuk Lymphoma 2012;Nov 26. doi: 10.3109/10428194.2012.745523. [Epub ahead of print]
   Web of Science ®Google Scholar
• Akkök CA, Hervig T, Stamnesfet S, Nesthus I, Melve GK, Lassalle P, Bruserud O. Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma. Cytotherapy 2011;13:1259–1268.
   PubMed Web of Science ®Google Scholar
• Dankbar B, Padró T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE, Kienast J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000;95:2630–2636.
   PubMed Web of Science ®Google Scholar
• Anderson KC. Moving disease biology from the laboratory to the clinic. Semin Oncol 2002;29:17–20.
   PubMed Web of Science ®Google Scholar
• Bhaskar A. Gupta R. Sreenivas V. Rani L. Kumar L. Sharma A. Sharma OD. Sharma MC. Thakur SC. Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma. Leuk Res 2013;37:410–415.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA. Barlogie B. Smith TL. Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 1991;115:931–935.
   PubMed Web of Science ®Google Scholar
• Kyrstsonis MC. Dedoussis G. Baxevanis C. Stamatelou M. Maniatis A. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM). Br J Haematol 1996;92:420–422.
   PubMed Web of Science ®Google Scholar
• Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80: 733–737.
   PubMed Web of Science ®Google Scholar
• Harris AL, Reusch P, Barleon B, Hang C, Dobbs N, Marme D. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 2001;7:1992–1997.
   PubMed Web of Science ®Google Scholar
• Chung NAY, Makin AJ, Lip GYH. Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay. Eur J Clin Invest 2003;33:529–535.
   PubMed Web of Science ®Google Scholar
• Chong AY, Caine GJ, Freestone B, Blann AD, Lip GY. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol 2004;43:423–428.
   PubMed Web of Science ®Google Scholar
• Findley CM, Cudmore MJ, Ahmed A, Kontos CD. VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol 2007;27:2619–2626.
   Google Scholar